Table 2.
Tumour markers in detection of pancreatobiliary versus intestinal histological type of differentiation in pancreatic head adenocarcinomas
| Histological type | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Pancreatobiliary | Intestinal | ||||||||
| Pos | Neg | Pos | Neg | Sensitivity, % | Specificity, % | P-value* | PPV (%) | 95% CI | |
| Pancreatobiliary markers | |||||||||
| CK7 | 65 | 2 | 33 | 13 | 97 | 28 | <0.001 | 66 | [56–75%] |
| MUC1 | 32 | 33 | 9 | 37 | 49 | 80 | 0.001 | 78 | [62–89%] |
| MUC4 | 23 | 44 | 4 | 42 | 34 | 91 | 0.002 | 85 | [65–95%] |
| Intestinal markers | |||||||||
| CK20 | 17 | 48 | 31 | 15 | 67 | 74 | <0.001 | 65 | [49–77%] |
| MUC2 | 1 | 64 | 6 | 40 | 13 | 98 | 0.020 | 86 | [42–99%] |
| CDX2 | 10 | 57 | 25 | 21 | 54 | 85 | <0.001 | 71 | [53–85%] |
PPV, Positive predictive value (i.e. the probability of obtaining a true positive test result); CI, Confidence interval; Pos, Immunopositivity; Neg, Immunonegativity (any nuclear reactivity was considered a positive sample for CDX2, whereas cytoplasmic reactivity in >10% of tumour cells defined a positive sample for the remaining markers); CK, Cytokeratin.
*
Fisher’s exact test, P-value for each marker versus the histological type determined morphologically.